Press Releases May 12, 2026 04:05 PM

Lifecore Biomedical to Participate at CDMO Live Europe

Lifecore Biomedical to showcase expertise at CDMO Live Europe conference

By Jordan Park LFCR

Lifecore Biomedical, a US-based injectable CDMO, announced its participation in the CDMO Live Europe conference held in Rotterdam. The company will engage in panel discussions and meetings to present its capabilities in sterile injectable pharmaceutical product development and manufacturing, focusing on process development and manufacturing services.

Lifecore Biomedical to Participate at CDMO Live Europe
LFCR

Key Points

  • Lifecore will participate in a key industry conference, CDMO Live Europe, including a panel on tech transfer strategies.
  • The company specializes in sterile injectable pharmaceutical products and is a leading manufacturer of injectable-grade hyaluronic acid.
  • Participation aims to strengthen relationships with prospective customers and showcase manufacturing expertise, supporting the biopharmaceuticals sector.

CHASKA, Minn., May 12, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at CDMO Live Europe. The conference will take place May 19-21, 2026, in Rotterdam, Netherlands.

Details regarding Lifecore’s participation are as follows:

  • CDMO Live Europe
    Details: Ryan Swanson, Ph.D., Lifecore’s director of manufacturing science and technology, will participate in a panel discussion, and the company will host meetings with prospective customers to discuss process development and manufacturing services for injectables programs.
    Panel Title: The Tech Transfer Playbook: Right First Time Strategies
    Panel Date/Time: May 19, 2026, 13:40 to 15:00
    Booth: Booth G-1
    Conference Dates/Location: May 19-21, 2026, in Rotterdam, Netherlands

If you are interested in meeting with Lifecore during CDMO Live Europe, please reach out to us at: [email protected].

About Lifecore Biomedical 
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.

Lifecore Biomedical, Inc. Contact Information:

Vida Strategic Partners
Stephanie Diaz (Investors)
415-675-7401
[email protected]

Jennifer Arcure (Media)
917-603-0681
[email protected]

Lifecore Biomedical
Ryan D. Lake (CFO)
952-368-6244
[email protected]


Risks

  • Outcomes depend on successful customer engagement and converting interest into contracts in a competitive CDMO market.
  • Participation in a conference is unlikely to generate immediate revenue impact, posing short-term uncertainty.
  • Broader pharmaceutical and CDMO industry dynamics, including pricing pressures and regulatory changes, could affect future growth prospects.

More from Press Releases

Vornado JV Completes $161 Million Refinancing of 61 Ninth Avenue May 12, 2026 New Era Energy & Digital Announces Participation in Upcoming Investor and Industry Conferences May 12, 2026 Upexi Reports Fiscal Third Quarter 2026 Financial Results May 12, 2026 Alignment Healthcare Strengthens Leadership Team to Support Long-Term Growth and Shareholder Value Creation May 12, 2026 RTB Digital and Ryvyl Inc. Merger Consummates, Name Change and Ticker Changed to RTB May 12, 2026